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Abstract
Heart failure (HF) is a crescent, solemn and multiple etiology worldwi-
de health problem, which, besides potentially fatal, decreases the life 
quality of the affected people, mainly the elderly. Despite having ob-
tained drugs that help in the disease development control, have been 
sought new alternatives for better management of these individuals. 
The LCZ696, a neprilysin inhibitor (sacubitril) associated with an ARB 
(valsartan) has shown significant improvements in patients' morbidity 
and mortality, which puts it as a good and interesting option for the 
treatment of heart failure.
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Heart failure (HF) is a global health problem with an estimated pre-
valence of over 5.8 million in the USA and over 23 million worldwide 
[1]. It represents the most common cause of hospitalization in elderly 
patients (≥ 65 years) and its incidence has a growing trend mainly 
due to the aging of the population [2, 3]. Although heart failure 
increases the risk of death, nonfatal worsening of symptoms is the 
most common problem encountered by patients, who experience 
progressive impairment of functional capacity and quality of life [4, 
5]. The important advances in the treatment of HF accomplished 
over the past decades in terms of drug and device therapy have 
resulted in a significant improvement in the prognosis in patients 
with chronic HF [6, 7].
Chronic heart failure is associated with a complex pattern of neu-
rohormonal activation that contributes to the relentless progression of 
this fatal syndrome [8, 9]. The activation of the sympathetic nervous 
system (SNS) and the renin-angiotensin-aldosterone system (RAAS) 
cause cardiac remodeling, leading to progressive cardiac dilatation and 
to dysfunction of the failing heart [10]. 
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The activation of detrimental neurohormonal 
pathways contributes to the clinical progression 
of heart failure [8]. Several peptides (ie, natriure-
tic peptides, bradykinin, and adrenomedullin) can 
attenuate vasoconstriction and sodium retention, 
and retard cardiac and vascular hypertrophy and 
remodeling, and thus act to ameliorate many of 
the pathophysiological abnormalities of heart failu-
re [5, 11-13]. Biologically active NPs are degraded 
by the enzyme neutral endopeptidase or neprilysin; 
consequently, neprilysin inhibition represents an im-
portant pharmacological approach to augment the 
salutary actions of NPs [14-16]. 
Simultaneous blockade of RAAS and neprilysin 
through dual-acting ACE and NEPi (vasopeptidase 
inhibitors) has been evaluated a decade ago, but 
further development was halted because of increa-
sed rates of angioedema, presumably caused by ac-
cumulation of bradykinin in at-risk patients [16-18].
LCZ696, which consists of the neprilysin inhibitor 
sacubitril (AHU377) and the ARB valsartan, was de-
signed to minimize the risk of serious angioedema 
[19-21], is a single molecule entity consisting of 2 
molecular moieties in a 1:1 molar ratio of valsartan, 
an ARB (angiotensin receptor blockers), and the NEP 
(neutral endopeptidase) inhibitor prodrug AHU377 
[22-23]. 
In August of 2014, the New England Journal of 
Medicine published the Prospective Comparison of 
angiotensin receptor-neprilysin inhibitor (ARNI) with 
angiotensin-converting–enzyme inhibitor (ACEI) to 
Determine Impact on Global Mortality and Morbi-
dity in Heart Failure (PARADIGM-HF) study, which 
compared the combination of an ARB þ neprilysin 
(LCZ696) head-to-head against an ACEI (enalapril) 
[21, 23]. 
The magnitude of these advantages of LCZ696 
over ACE inhibition was highly significant and cli-
nically important, particularly since the drug was 
compared with a dose of enalapril that has been 
shown to reduce mortality, as compared with pla-
cebo [21, 24, 25].
The 20% reduction in cardiovascular deaths with 
LCZ696 relative to enalapril seen during the trial was 
attributable primarily to reductions in the incidence 
of both sudden death and death due to progres-
sive heart failure. There was no discernible impact 
of LCZ696 relative to enalapril on the incidence of 
non-cardiovascular death [26]. 
Because of its greater vasodilator effects, 
treatment with LCZ696 was associated with a hig-
her rate of symptomatic hypotension, but there was 
no increase in the rate of discontinuation because 
of possible hypotension-related adverse effects [21]. 
The precise mechanism by which LCZ696 in-
fluences cardiovascular mortality is uncertain, and 
requires further study. Understanding the precise 
mechanism of benefit of LCZ696 in heart failure 
may provide important insights into the pathophy-
siology of heart failure and should be a priority for 
future study [26]. 
The Heart Failure has great worldwide impact, 
directly affecting the morbidity and mortality of the 
population, especially in the elderly. Understanding 
complex mechanism that generates Heart Failure in 
the body and act as new drugs, in particular LCZ696, 
currently known as the Association of Valsartan/Sa-
cubitril, is essential for the treatment we optimize 
and improve the quality of life of the patients. With 
the recent publication of a large trial, the efficacy of 
LCZ696 compared to enalapril, a drug already esta-
blished in the treatment of Heart Failure, was clear 
and encouraging, and led to the beginning of a 
new perspective in the treatment of this pathology. 
New research should arise and probably elucidate 
possible remaining doubt, and probably confirmed 
the real effect of LCZ696 concretely.
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